P-43 INDICATORS OF RESPONSE TO FIRST TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN HEPATOCELULLAR CARCINOMA

Introduction

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Liver transplantation offers good results in its treatment, however the shortage of donors has forced the use of other therapies, such as transarterial chemoembolization (TACE), whose therapeutic scheme is not completely standardized.

Objective

To evaluate the response to the first TACE, the indicators of success of the therapy and the decompensations associated with its use.

Methods

Retrospective observational study. 76 patients were included. Variables such as sociodemographic, clinical and HCC stages were included. Response to TACE was assessed by post-treatment LIRADS classification. Descriptive statistics were used for the analysis.

Results

60% men, the median age was 64 years (51-81), 63% Child A, average MELD-Na 10 points. 33% associated with NASH. 47% of the patients reached non-viability after the first TACE, 30% required two TACE, 15% three TACE and 7% four TACE. 58% in Barcelona stage A, 43% within the Milan criteria and 60% within the San Francisco criteria. 6% presented decompensations after the 1st TACE. The characteristics of the patients who reached non-viability versus those who remained viable are presented in Table 1.

Conclusion

Most patients require two TACEs to achieve tumor non-viability. The main indicators of response to TACE were tumor burden and MELD-Na score> 8.